Accessibility Menu
 
Adc Therapeutics logo

Adc Therapeutics

(NYSE) ADCT

Current Price$3.80
Market Cap$480.23M
Since IPO (2020)-87%
5 Year-85%
1 Year+184%
1 Month-7%

Adc Therapeutics Financials at a Glance

Market Cap

$480.23M

Revenue (TTM)

$81.36M

Net Income (TTM)

$142.62M

EPS (TTM)

$-1.20

P/E Ratio

-3.15

Dividend

$0.00

Beta (Volatility)

1.43 (Average)

Price

$3.80

Volume

40,453

Open

$3.65

Previous Close

$3.80

Daily Range

$3.63 - $3.96

52-Week Range

$1.05 - $4.98

ADCT News

No articles available.

ADCT: Motley Fool Moneyball Superscore

59

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Adc Therapeutics

Industry

Biotechnology

Employees

193

CEO

Ameet Mallik, MBA

Headquarters

Epalinges, 1066, CH

ADCT Financials

Key Financial Metrics (TTM)

Gross Margin

91%

Operating Margin

-1%

Net Income Margin

-2%

Return on Equity

0%

Return on Capital

-43%

Return on Assets

-44%

Earnings Yield

-31.75%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$480.23M

Shares Outstanding

127.04M

Volume

40.45K

Short Interest

0.00%

Avg. Volume

813.79K

Financials (TTM)

Gross Profit

$73.68M

Operating Income

$108.38M

EBITDA

$106.50M

Operating Cash Flow

$141.17M

Capital Expenditure

$264.00K

Free Cash Flow

$141.44M

Cash & ST Invst.

$261.34M

Total Debt

$439.01M

Adc Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$23.06M

+36.4%

Gross Profit

$19.48M

+25.4%

Gross Margin

84.50%

N/A

Market Cap

$480.23M

N/A

Market Cap/Employee

$1.83M

N/A

Employees

263

N/A

Net Income

$6.41M

+79.1%

EBITDA

$11.81M

+37.3%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$177.67M

-238.9%

Accounts Receivable

$29.12M

+43.3%

Inventory

$4.18M

-77.2%

Long Term Debt

$437.05M

+259.3%

Short Term Debt

$3.00M

+118.8%

Return on Assets

-44.14%

N/A

Return on Invested Capital

-42.84%

N/A

Free Cash Flow

$31.13M

-41.9%

Operating Cash Flow

$31.12M

-42.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
FDMT4D Molecular Therapeutics, Inc.
$9.48-3.95%
LCTXLineage Cell Therapeutics, Inc.
$1.57-1.26%
AUTLAutolus Therapeutics plc
$1.41+2.17%
BCYCBicycle Therapeutics plc
$5.05+3.06%

Trending Stocks

Symbol / CompanyPricePrice Chg
SKYQSky Quarry
$5.10+1.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$11.37-0.11%
INTCIntel
$50.38+0.05%
TQQQProShares Trust - ProShares UltraPro Qqq
$43.33+0.00%

Questions About ADCT

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.